Skip to main content
. 2026 Feb 27;17:2329. doi: 10.1038/s41467-026-70012-2

Fig. 4. Construction of PB@PM and its cardiac targeting efficacy.

Fig. 4

A Representative SEM image of PB. Scale bar: 200 nm. B Representative TEM image of PB. Scale bar: 200 nm. C Element mapping of PB. Scale bar: 100 nm. D TEM image of PB@PM. Scale bar: 50 nm. E Western blot analysis of CD41, CD42b, CD47, and GP6 expression in PM and PB@PM. Scale bar: 50 nm. F Fluorescence colocalization of PB and PM in PB@PM, and control represents a direct mixture of FITC-labeled PB (green) and Dil-labeled PM (red). Scale bar: 10 μm. G Typical ex vivo fluorescence images of major organs at 12 and 24 h after administration of Cy5.5-labeled PB (Sham mice; Control group), Cy5.5-labeled PB (MIRI mice; PB group), and Cy5.5-labeled PB@PM (MIRI mice; PB@PM group). H, I Quantitative analysis of the fluorescence intensities from separated hearts, livers, spleens, lungs, and kidneys in each group at 12 and 24 h, respectively (n = 3 biologically independent replicates). Exact P-values from upper to lower: (12 h-heart) 8.70E-07, 9.50E-07, 0.8948; (24 h-heart) 0.0442; (12 h-liver) 0.6819; (24 h-liver) 0.9998; (12 h-spleen) 0.1353; (24 h-spleen) 0.9857; (12 h-lung) 0.0654; (24 h-lung) 0.0599; (12 h-kidney) 0.9741; (24 h-kidney) 0.8667. Data are expressed as mean ± SD. P- values were calculated by one-way ANOVA with Tukey’s correction. *P < 0.05, **P < 0.01, ***P < 0.001, and ns implies P > 0.05. Source data are provided as a Source Data file.